GE’s Genomic Future

GE’s Genomic Future On its face, General Electric’s $9.5 billion stock purchase of Amersham is about imaging systems. But the more far-reaching consequences of the deal puts GE on the cutting edge of how new knowledge about genetics is used to treat patients. The deal could put General Electric in direct competition with diagnostic and […]


Get email updates

Get new actionable insights and updates from BiotechBlog

Do NOT follow this link or you will be banned from the site!